FDA consultants must make new efforts to disclose their business relationships before serving on advisory panels that help determine whether a new medical device or drug gains access to the U.S. market.
The federal watchdog agency this week put the final touches on new guidance that requires a pair of new forms from prospective advisory panelists.
One form requires acknowledgment of potential conflicts of interest and consent to disclosure of those relationships. The second outlines the FDA’s authority to accept an advisor despite potential conflicts.
The disclosure won’t be made largely public, the agency noted, keeping in line with previous conflict of interest policies for FDA advisors, according to Law360.com.